api 2

Triciribine (NSC-154020) is a DNA synthesis inhibitor, and it also inhibits Akt and HIV-1/2.

ADAM-17 (TACE) and MMP inhibitor (Ki = 120 nM at ADAM-17). Sensitizes cancer stem cells to the lethal effects of 5-FU in vitro. Blocks shedding of TNF-α from cell membranes.

FAPI-2 is a specific inhibitor of fibroblast-activated protein based on the radiotracer FAP labeling. It has anticancer activity and can be used in the study of pancreatic cancer.

DOTAGA.(SA.FAPi)2 TFA is an effective dimeric fibroblast activation protein inhibitor (FAPi). This compound holds potential for use in cancer diagnostic research.

NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia

lifastuzumAb is a humanized IgG1-like monoclonal antibody against NaPi2b, often coupled with the anti-mitotic agent monomethyl auristatin E, which inhibits cell division by blocking the polymerization of microtubule proteins.

NaPi2b-IN-2 (compound 5) is a potent inhibitor of the sodium-dependent transport protein 2b (SLC34A2, NaPi2b), with an IC50 of 38 nM against human NaPi2b. It holds potential for hyperphosphatemia research [1].

FAPI-2 TFA, a fibroblast activation protein (FAP) inhibitor, is potentially applicable in cancer research [1].

Lifastuzumab vedotin is an antibody-drug conjugate (ADC) that blocks cell division by inhibiting tubulin polymerization, with potential applications in the research of non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC).

TAPI-2 is a broad-spectrum inhibitor of MMP (IC50: 20 μM), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM).

SKQ1, also known as Visomitin or plastoquinonyl decyltriphenyl phosphonium (PDTP), is a potent mitochondrial-targeted antioxidant. As the active pharmaceutical ingredient (API) in Visomitin eye drops, SKQ1 exhibits various biomedical activities: (1) prevents impairment of long-term potentiation in rat hippocampal slices caused by amyloid β-protein; (2) reverses aging-related biomarkers in rats; (3) slows age-related degenerative changes in the retinas and choroid of Wistar and OXYS rats; (4) extends the lifespan of male rodents in LP or SPF conditions. SKQ1 can penetrate cell membranes and is proposed for use in anti-aging therapies. Clinical trials for SKQ1 are currently underway in Russia to treat glaucoma. For convenience, SKQ1 is provided as an ethanol-water (1:1, v/v) solution at a concentration of 200 mg/mL.